Protection for an unpredictable world
We are developing cutting-edge vaccines by utilizing our innovative adjuvant technology and our expertise of Toll-like Receptor (TLR) biology to modulate the immune system.
HEPLISAV-B®
[HEPATITIS B VACCINE (RECOMBINANT) ADJUVANTED]
COVID-19 Information and Resources
During the uncertainty caused by the COVID-19 pandemic, Dynavax has acted quickly to focus on four key areas – these include safeguarding the health and safety of our employees and customers; continuing effective operations to ensure patient access to HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted]; maintaining our financial strength and stability; and supporting efforts to develop a COVID-19 vaccine.
